Clozapine remains the only medication approved for treatmentresistant schizophrenia. But underuse is the norm. In 2010, the New York State Office of Mental Health began a multifaceted initiative to promote the evidence-based use of clozapine. From 2009 to 2013, in the absence of a wellfunded pharmaceutical marketing campaign, the proportion of newclozapine trials among all newoutpatient antipsychotic trials increased 40% among adult New York Medicaid recipients with a diagnosis of schizophrenia. The largest gains occurred in state-operated clinics. New York's experience demonstrates the feasibility of making clozapine more accessible to patients who stand to benefit most.
ASJC Scopus subject areas
- Psychiatry and Mental health